🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Recruitingn/aAges 60 Years - anyAllFrench Innovative Leukemia Organisation
NCT06891144 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recen

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 60 and over * Patients with previously untreated de novo or secondary AML * Patients suitable for standard intensive treatment * Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent). Exclusion Criteria: * Patients with AML 3 * Patients with severe, uncontrolled infection at the time of inclusion * Patients with psychiatric or social disorders that will prevent compliance with the protocol * Patients without health insurance (affiliation to a social security scheme)
💊

What it tests

  • Not listed
📍

Where

27 sites
Angers CHU
Angers, France
Annecy CH
Annecy, France
Avignon CH
Avignon, France
Bayonne CH
Bayonne, France
Besançon CHU
Besançon, France
Brest CHU
Brest, France
CHU Estaing
Clermont-Ferrand, France
Colmar CH
Colmar, France

…and 19 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy